Skip to main content
Evidence-Based Supplement Research
Evidence-Based Supplement Research

HMGB1-antagonism exerted by glycyrrhizin could be fruitful against COVID-19.

  • 2021-10-01
  • Acta bio-medica : Atenei Parmensis 92(S6)

Study Design

Type
Review
The COVID-19 pandemic era is causing a relevant issue for the health. There is no specific drug able to antagonize the SARS-CoV-2 infection. As a consequence, there is growing interest about potential molecules able to contrast infection. In this regard, HMGB, an alarmin, may play a relevant role in pathogenic mechanisms induced by SARS-CoV-2.  As HMGB1 is antagonized by glycyrrhizin, this substance could be potentially useful as ancillary treatment in COVID-19.

Research Insights

    Back to top